Achema middle east

Purdue Pharma announces availability of insomnia drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CMS Unveils a New Voluntary Access Programme For GLP-1

In the most recent of a string of announcements ahead...

Bevacizumab to be Used by NHS for Colorectal Cancer

NICE has gone ahead and cleared the way for...

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...
- Advertisement -

Purdue Pharma has announced the availability of Intermezzo sublingual tablet CIV in 1.75mg and 3.5mg dosage strengths for insomnia characterized by middle-of-the-night awakenings followed by difficulty returning to sleep.

Intermezzo (zolpidem tartrate), which contains a bicarbonate-carbonate buffer, is available in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. The product is available on prescription in retail pharmacies in the US, the company said.

Purdue Pharma president and CEO John Stewart said: “We are confident that healthcare professionals will find Intermezzo to be a valuable therapeutic option.”

Latest stories

Related stories

CMS Unveils a New Voluntary Access Programme For GLP-1

In the most recent of a string of announcements ahead...

Bevacizumab to be Used by NHS for Colorectal Cancer

NICE has gone ahead and cleared the way for...

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »